Stocktoria
EXAGEN INC. XGN
Nasdaq · XNAS · stock · Services-Medical Laboratories · website · IPO 2019-09-19
EXAGEN INC. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 58.3% | 59.5% | 56.1% | — | — |
| Operating margin | -21.1% | -24.5% | -43.5% | -101.1% | -49.8% |
| Net margin | -30.0% | -27.2% | -45.1% | -104.0% | -55.6% |
| FCF margin | -21.4% | -24.8% | -29.1% | -80.0% | -46.9% |
| Return on assets | -34.4% | -33.8% | -41.6% | -55.0% | -21.8% |
| Return on equity | -114.3% | -158.4% | -104.4% | -111.6% | -31.6% |
| Debt / equity | 1.31× | 2.12× | 0.86× | 0.68× | 0.32× |
| Current ratio | 3.45 | 2.70 | 4.02 | 7.55 | 12.10 |
| Revenue growth | 19.7% | 5.9% | 15.3% | -5.7% | 15.1% |
Source: SEC EDGAR filings · CIK 0001274737 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.